Oxide

Oxide Debt/EBITDA

The Total Debt to EBITDA Ratio of Oxide (6521.T) as of Nov 2, 2026 is 13.90. In the previous year, Total Debt to EBITDA Ratio was 27.51 — a change of -49.49% (lower).

Debt/EBITDA

13.90

YoY

-49.49%

Last updated:

Total Debt to EBITDA Ratio of Oxide is 2026 13.90 . Total Debt to EBITDA Ratio of Oxide was 2025 27.51 . It decreases by -49.49% lower compared to the previous year.

The Oxide Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
18.82 JPY
Jan 1, 2020
13.77 JPY
Jan 1, 2021
8.48 JPY
Jan 1, 2022
4.23 JPY
Jan 1, 2023
6.50 JPY
Jan 1, 2024
-12.41 JPY
Jan 1, 2025
27.51 JPY
Jan 1, 2026
13.90 JPY
The Oxide Debt/EBITDA history
YEARDebt/EBITDAYoY
13.90-49.49%
27.51-321.72%
-12.41-290.84%
6.50+53.64%
4.23-50.09%
8.48-38.43%
13.77-26.85%
18.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oxide Stock analysis

What does Oxide do? OXIDE Corp. generates revenue through the development, manufacture, and sale of electronic components across multiple segments. The Optical segment produces single crystals, optical components, laser light sources, and optical measuring devices for equipment manufacturers and optical product manufacturers. Scintillator single crystals are utilized in positron emission tomography (PET) testing equipment for cancer diagnosis, while laser light sources are integrated into quality inspection devices for silicon wafers in semiconductor manufacturing. Products are primarily sold to companies in the optical measurement, semiconductor, and healthcare sectors. The company's revenue streams are derived from three core business areas: optical measurement, semiconductor, and healthcare. Equipment manufacturers and optical product manufacturers purchase optical components and devices, while semiconductor companies use laser light sources for wafer quality inspection. Healthcare providers rely on scintillator single crystals for PET testing equipment. These segments collectively drive the company's sales and market presence. OXIDE Corp. focuses on supplying specialized components to industries requiring precision optical solutions. The Optical segment's products serve as critical inputs for medical diagnostics and semiconductor production, ensuring consistent demand from established industry players. Sales are concentrated among equipment manufacturers, optical product manufacturers, semiconductor companies, and healthcare providers within the specified business fields. Oxide is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oxide stock

Total Debt to EBITDA Ratio of Oxide is 13.90 in 2026.

Total Debt to EBITDA Ratio of Oxide changed from 27.51 to 13.90, representing a -49.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Oxide since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Oxide with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Oxide

All Key Metrics — Oxide